Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapeutics to combat antibiotic-resistant infections globally. Utilizing its proprietary bacteriophage-based technology, the company is advancing product candidates such as AP-SA02, aimed at treating Staphylococcus aureus bacteremia, AP-PA02 for combatting Pseudomonas aeruginosa, and AP-PA03 for the treatment of pneumonia. The company's stock is identified with the symbol 'ARMP' in the market. In terms of financial performance, the net income ratio is 0.00 reflecting the company's profitability margin. The company incurred an interest expense of -$10,742,000.00 indicating its debt servicing obligations. Additionally, its operating expenses amount to $47,610,000.00 encompassing various costs associated with its operations. The diluted EPS is -$0.32 which takes into account potential share dilution. Armata has also established a partnership agreement with Merck & Co. to collaborate on developing synthetic bacteriophage candidates aimed at tackling undisclosed infectious disease agents. Headquartered in Marina del Rey, California, Armata is strategically positioned within the healthcare landscape. The stock is currently affordable at $2.17 making it suitable for budget-conscious investors. However, it has a low average trading volume of 245,428.00 indicating lower market activity and potentially affecting liquidity. With a market capitalization of $70,577,325.00 the company is classified as a small-cap player, which could appeal to investors seeking opportunities in emerging markets. It plays a significant role in the Biotechnology industry, contributing meaningfully to the overall market landscape and addressing critical health challenges. Moreover, it belongs to the Healthcare sector, driving innovation and growth within the biotechnology sphere. The dynamics of its financial metrics, combined with its strategic position in the market, enhance its profile as a company focused on pioneering solutions in the face of rising antibiotic resistance.